liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients
Department of Laboratory Medicine, Lund University, Malmö University Hospital, S-205 02 Malmö, Sweden, Department of Medicine, Ryhov Regional Hospital, Jönköping, Sweden.
Rydén, L., Department of Laboratory Medicine, Lund University, Malmö University Hospital, S-205 02 Malmö, Sweden.
Linköping University, Faculty of Health Sciences. Linköping University, Department of Clinical and Experimental Medicine, Oncology . Östergötlands Läns Landsting, Centre of Surgery and Oncology, Department of Oncology UHL.
Jönsson, P.E., Department of Surgery, Helsingborg Hospital, Helsingborg, Sweden.
Show others and affiliations
2006 (English)In: Clinical Cancer Research, ISSN 1078-0432, Vol. 12, no 15, 4614-4618 p.Article in journal (Refereed) Published
Abstract [en]

Purpose: Tamoxifen has long been the drug of choice in adjuvant endocrine therapy of steroid hormone receptor-positive breast cancer, and it still remains important due to its well-documented beneficial effect. Hormone receptor status is often reported as "positive" or "negative" using 10% positive nuclei as a cutoff. In this study, we aimed to assess whether a further subclassification of hormone receptor status could enhance the treatment predictive value. Experimental Design: The immunohistochemical expression of estrogen receptor (ER) and progesterone receptor (PR) was quantified in tissue microarrays with tumors from 500 premenopausal breast cancer patients previously included in a randomized trial of adjuvant tamoxifen compared with an untreated control group. Results: Our findings show a gradually increasing tamoxifen effect in tumors with >10% ER-positive nuclei. However, when analyzing tamoxifen response according to various PR fractions, we found that it was primarily patients with tumors showing >75% PR-positive nuclei that responded to tamoxifen treatment, with an improved recurrence-free [relative risk, 0.42 (0.25-0.70), P = 0.001] as well as overall [relative risk, 0.49 (0.28-0.84), P = 0.010] survival. Conclusions: Adjuvant tamoxifen improved recurrence-free and overall survival for premenopausal patients with tumors showing >75% PR-positive nuclei. No effect could be shown in tumors with fewer PR-positive nuclei. The PR was a stronger predictor of treatment response than the ER. Based on these findings, we suggest the implementation of a fractioned rather than dichotomized immunohistochemical evaluation of hormone receptors in clinical practice, possibly with greater emphasis on the PR than the ER. © 2006 American Association for Cancer Research.

Place, publisher, year, edition, pages
2006. Vol. 12, no 15, 4614-4618 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-50166DOI: 10.1158/1078-0432.CCR-06-0248OAI: diva2:271062
Available from: 2009-10-11 Created: 2009-10-11 Last updated: 2011-01-11

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Nordenskjöld, Bo
By organisation
Faculty of Health SciencesOncology Department of Oncology UHL
In the same journal
Clinical Cancer Research
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 10 hits
ReferencesLink to record
Permanent link

Direct link